论文部分内容阅读
目的了解慢性心力衰竭病例β-受体阻滞剂的应用情况。方法对慢性心衰患者应用β-受体阻滞剂的情况进行问卷调查。结果入选1 238例,门诊病例427例,住院病历811例。临床诊断依次是冠心病(43.8%)、高血压性心脏病(16.7%)、风湿性心脏病(14.7%)、肺心病(8.8%)、扩张型心肌病(6.8%)等。入选病例心功能以纽约心功能分级(NYHA)Ⅱ~Ⅳ级。治疗药物在应用硝酸酯类、利尿剂、洋地黄制剂的基础上应用β-受体阻滞剂,β-受体阻滞剂的应用无性别和年龄差异。结论慢性心衰住院病例的治疗药物传统以利尿剂、硝酸酯制剂和洋地黄制剂等为主,随着临床研究的发展,β-受体阻滞剂的应用逐年增加,但仍未达到“指南”的要求,须不断更新治疗观念,使更多的心衰患者受益。
Objective To understand the use of β-blockers in patients with chronic heart failure. Methods Chronic heart failure patients using β-blockers were surveyed. Results A total of 1 238 cases were selected, 427 were outpatients and 811 were hospitalized. The clinical diagnosis was followed by coronary heart disease (43.8%), hypertensive heart disease (16.7%), rheumatic heart disease (14.7%), cor pulmonale (8.8%) and dilated cardiomyopathy (6.8%). Selected cases of cardiac function in New York Cardiac Function Classification (NYHA) Ⅱ ~ Ⅳ level. Therapeutic drugs in the application of nitrates, diuretics, digitalis based on the application of β-blockers, β-blockers for non-gender and age differences. CONCLUSIONS: The traditional therapeutic drugs for inpatients with chronic heart failure are mainly diuretics, nitrates preparations and digitalis preparations. With the development of clinical research, the application of β-blockers has been increasing year by year but has not yet reached the guideline "Requirements, must constantly update the treatment concept, so that more patients with heart failure benefit.